Revised: 19 April 2024
Information for Healthcare Professionals
This section provides information useful to healthcare professionals.
Medsafe Advice
| Date | Type | Title |
|---|---|---|
| 16/1/2025 | Monitoring Communication |  Anti-CD20 monoclonal antibodies (rituximab, ocrelizumab, obinutuzumab, ofatumumab) and the possible risk of pyoderma gangrenosum - Monitoring closes 16 July 2025 |
| 7/1/2025 | Notices | Notice of Medsafe Office Closure Christmas/New Year 2024/2025 |
If you have an enquiry that is not answered by the information on the web site please contact us at askmedsafe@health.govt.nz.
